Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harmony Biosciences Holdings (HRMY) Common Equity (2019 - 2025)

Harmony Biosciences Holdings (HRMY) has disclosed Common Equity for 7 consecutive years, with $870.2 million as the latest value for Q4 2025.

  • Quarterly Common Equity rose 32.02% to $870.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $870.2 million through Dec 2025, up 32.02% year-over-year, with the annual reading at $870.2 million for FY2025, 32.02% up from the prior year.
  • Common Equity hit $870.2 million in Q4 2025 for Harmony Biosciences Holdings, up from $835.1 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $870.2 million in Q4 2025 to a low of $107.9 million in Q1 2021.
  • Historically, Common Equity has averaged $458.3 million across 5 years, with a median of $474.2 million in 2023.
  • Biggest five-year swings in Common Equity: skyrocketed 126.21% in 2022 and later grew 11.01% in 2024.
  • Year by year, Common Equity stood at $186.5 million in 2021, then skyrocketed by 115.99% to $402.8 million in 2022, then grew by 15.93% to $467.0 million in 2023, then soared by 41.15% to $659.2 million in 2024, then surged by 32.02% to $870.2 million in 2025.
  • Business Quant data shows Common Equity for HRMY at $870.2 million in Q4 2025, $835.1 million in Q3 2025, and $773.1 million in Q2 2025.